If You Invested $10,000 In Johnson & Johnson Stock 10 Years Ago, How Much Would You Have Now?

Johnson & Johnson JNJ researches, develops, manufactures and sells various products in the health care field worldwide.

It is set to report its Q1 2025 earnings on April 15. Wall Street analysts expect the company to post an EPS of $2.67, down from $2.71 in the year-ago period. According to Benzinga Pro, quarterly revenue is expected to reach $22.04 billion, up from $21.38 billion in the previous year.

If You Bought Johnson & Johnson Stock 10 Years Ago

The company's stock traded at approximately $102.26 per share 10 years ago. If you had invested $10,000, you could have bought roughly 98 shares. Currently, shares trade at $146.64, meaning your investment's value could have grown to $14,340 from stock price appreciation alone. However, Johnson & Johnson also paid dividends during these 10 years. 

Don't Miss:

• Unlock the hidden potential of commercial real estate — This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!
• This Jeff Bezos-backed startup will allow you to become a landlord in just 10 minutes, with minimum investments as low as $100.

Johnson & Johnson's dividend yield is currently 3.38%. Over the last 10 years, it has paid about $37.93 in dividends per share, which means you could have made $3,709 from dividends alone. 

Summing up $14,340 and $3,709, we end up with the final value of your investment, which is $18,049. This is how much you could have made if you had invested $10,000 in Johnson & Johnson stock 10 years ago. This means a total return of 80.49%. However, this figure is significantly less than the S&P 500 total return for the same period, which was 237.69%.

Trending: It’s no wonder Jeff Bezos holds over $70 million in art — this alternative asset has outpaced the S&P 500 since 1995, delivering an average annual return of 11.4%. Here’s how everyday investors are getting started.

What Could The Next 10 Years Bring? 

Johnson & Johnson has a consensus rating of "Neutral" and a price target of $164.68 based on the ratings of 22 analysts. The price target implies more than a 12% upside from the current stock price.

On Jan. 22, the company announced its Q4 2024 earnings, posting an adjusted EPS of $2.04, down 10.9% year-over-year, beating the consensus of $2.01, as reported by Benzinga.

The pharmaceutical giant reported sales of $22.52 billion, up 5.3% year-over-year, beating the consensus of $22.44 billion. Operational growth was 6.7% and adjusted operational growth was 5.7%.

See Also: Commercial real estate has historically outperformed the stock market, and this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!

Johnson & Johnson expects 2025 sales of $90.9 billion –$91.7 billion, compared to the consensus of $90.99 billion. The Medtech giant expects 2025 adjusted EPS of $10.75 –$10.95 versus a consensus of $10.59.

The company expects to accelerate the launch of newly launched products in the MedTech segment, with the full benefit of the Shockwave acquisition through May. JNJ sees normalized procedure volume and seasonality.

Check out this article by Benzinga for 12 analysts' insights on Johnson & Johnson.

Growth-focused investors may find Johnson & Johnson stock attractive given the expected upside potential. Furthermore, they can benefit from the company's solid dividend yield of 3.38% and consistent hikes. Johnson & Johnson has raised its dividend consecutively for the last 62 years.

Wondering if your investments can get you to a $5,000,000 nest egg? Speak to a financial advisor today. SmartAsset’s free tool matches you up with up to three vetted financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.

A 9% Return In Just 3 Months

EquityMultiple's ‘Alpine Note — Basecamp Series' is turning heads and opening wallets. This short-term note investment offers investors a 9% rate of return (APY) with just a 3 month term and $5K minimum. The Basecamp rate is at a significant spread to t-bills. This healthy rate of return won't last long. With the Fed poised to cut interest rates in the near future, now could be the time to lock in a favorable rate of return with a flexible, relatively liquid investment option. 

What's more, Alpine Note — Basecamp can be rolled into another Alpine Note for compounding returns, or into another of EquityMultiple's rigorously vetted real estate investments, which also carry a minimum investment of just $5K. Basecamp is exclusively open to new investors on the EquityMultiple platform.

Looking for fractional real estate investment opportunities? The Benzinga Real Estate Screener features the latest offerings.